» Articles » PMID: 22084439

Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells

Overview
Journal J Immunol
Date 2011 Nov 16
PMID 22084439
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Perioperative injuries to an allograft exacerbate graft rejection, which in humans is primarily mediated by effector memory T cells. IL-6 transcripts in human coronary artery segments rapidly increase posttransplantation into immunodeficient mouse hosts compared with those of pretransplant specimens and fall dramatically by 30 d. Adoptive transfer of human PBMCs allogeneic to the artery 2 d postoperatively results in T cell infiltrates and intimal expansion 4 wk later. Ab neutralization of human IL-6 reduces the magnitude of intimal expansion and total T cell infiltration but increases the relative expression of CD161 while decreasing other Th17 markers. Coculture of MHC class II-expressing human endothelial cells (ECs) with allogeneic CD4(+) memory T cells results in T cell activation and EC secretion of IL-6. Neutralizing IL-6 in primary allogeneic T cell-EC cocultures results in enhanced T cell proliferation of CD161(+) CD4(+) T cells, reduces total T cell proliferation upon restimulation in secondary cultures (an effect dependent on CD161(+) T cells), increases expression of FOXP3 in CD161(+) T cells, and generates T cells that suppress proliferation of freshly isolated T cells. These data suggest that IL-6 released from injured allograft vessels enhances allogeneic T cell infiltration and intimal expansion in a model of human allograft rejection by inhibiting an increase in CD161(+) regulatory T cells.

Citing Articles

Innate immune modulation in transplantation: mechanisms, challenges, and opportunities.

Praska C, Tamburrini R, Danobeitia J Front Transplant. 2024; 2:1277669.

PMID: 38993914 PMC: 11235239. DOI: 10.3389/frtra.2023.1277669.


Translating B cell immunology to the treatment of antibody-mediated allograft rejection.

Heeger P, Haro M, Jordan S Nat Rev Nephrol. 2024; 20(4):218-232.

PMID: 38168662 DOI: 10.1038/s41581-023-00791-0.


Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade.

Berger M, Baliker M, van Gelder T, Bohmig G, Mannon R, Kumar D Transplantation. 2023; 108(5):1109-1114.

PMID: 37941113 PMC: 11042519. DOI: 10.1097/TP.0000000000004822.


Strategies to Overcome HLA Sensitization and Improve Access to Retransplantation after Kidney Graft Loss.

Leal R, Pardinhas C, Martinho A, Sa H, Figueiredo A, Alves R J Clin Med. 2022; 11(19).

PMID: 36233621 PMC: 9572793. DOI: 10.3390/jcm11195753.


IL-6 Directed Therapy in Transplantation.

Miller C, Madsen J Curr Transplant Rep. 2021; 8(3):191-204.

PMID: 34099967 PMC: 8173333. DOI: 10.1007/s40472-021-00331-4.


References
1.
Nadig S, Wieckiewicz J, Wu D, Warnecke G, Zhang W, Luo S . In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med. 2010; 16(7):809-13. PMC: 2929438. DOI: 10.1038/nm.2154. View

2.
Perez-Villa F, Benito B, Llancaqueo M, Cuppoletti A, Roig E . Elevated levels of serum interleukin-6 are associated with low grade cellular rejection in patients with heart transplantation. Transplant Proc. 2006; 38(9):3012-5. DOI: 10.1016/j.transproceed.2006.08.113. View

3.
Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B . How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009; 102(2):215-22. DOI: 10.1160/TH09-05-0297. View

4.
Wei L, Kuo M, Chen C, Chou C, Lai K, Lee C . Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003; 22(10):1517-27. DOI: 10.1038/sj.onc.1206226. View

5.
Knoechel B, Lohr J, Kahn E, Bluestone J, Abbas A . Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005; 202(10):1375-86. PMC: 2212975. DOI: 10.1084/jem.20050855. View